In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations

被引：60

作者：

Farrell, DJ ^{[1
]}

Morrissey, I ^{[1
]}

Bakker, S ^{[1
]}

Buckridge, S ^{[1
]}

Felmingham, D ^{[1
]}

机构：

[1] GR Micro Ltd, London NW1 3ER, England

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 08期

关键词：

D O I：

10.1128/AAC.48.8.3169-3171.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

To date, 86 of 7,746 macrolide-resistant Streptococcus pneumoniae isolates from 1999 to 2002 PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) surveillance studies were negative for methylase and efflux mechanisms. Mutations in 23S rRNA or the genes encoding riboprotein L4 or L22 were found in 77 of 86 isolates. Six isolates were resistant to quinupristin-dalfopristin and two were resistant to linezolid, while telithromycin demonstrated good activities against all isolates.

引用

收藏

页码：3169 / 3171

页数：3

相关论文

共 11 条

[1] Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae [J].

Canu, A ;

Malbruny, B ;

Coquemont, M ;

Davies, TA ;

Appelbaum, PC ;

Leclercq, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :125-131

[2] Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae [J].

Depardieu, F ;

Courvalin, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :319-323

[3] Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study [J].

Farrell, DJ ;

Douthwaite, S ;

Morrissey, I ;

Bakker, S ;

Poehlsgaard, J ;

Jakobsen, L ;

Felmingham, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1777-1783

[4] Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study [J].

Farrell, DJ ;

Morrissey, I ;

Bakker, S ;

Felmingham, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :39-47

[5] Detection of macrolide resistance mechanisms in Streptococcus pneumonide and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization [J].

Farrell, DJ ;

Morrissey, I ;

Bakker, S ;

Felmingham, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :541-544

[6] Quinupristin-dalfopristin resistance in Streptococcus pneumoniae:: Novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY Antimicrobial Surveillance Program [J].

Jones, RN ;

Farrell, DJ ;

Morrissey, I .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2696-2698

[7] Emergence of macrolide resistance during treatment of pneumococcal pneumonia [J].

Musher, DM ;

Dowell, ME ;

Shortridge, VD ;

Flamm, RK ;

Jorgensen, JH ;

Le Magueres, P ;

Krause, KL .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) :630-631

[8]

National Committee for Clinical Laboratory Standards - NCCLS, 2004, M100S14 NCCLS

[9] Ribosomal mutations in Streptococcus pneumoniae clinical isolates [J].

Pihlajamäki, M ;

Kataja, J ;

Seppälä, H ;

Elliot, J ;

Leinonen, M ;

Huovinen, P ;

Jalava, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :654-658

[10] Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage [J].

Tait-Kamradt, A ;

Davies, T ;

Cronan, M ;

Jacobs, MR ;

Appelbaum, PC ;

Sutcliffe, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2118-2125